Upstream & Downstream Processing

Proteinea using fly larvae as ‘mini-bioreactors’ in challenge to industry

Producing recombinant proteins in fly larvae instead of single-cell technologies could reduce biomanufacturing costs by up to 90%, says bioprocess startup firm Proteinea. Proteinea, a US and Egyptian startup, is looking to change the economics of biomanufacturing. The firm challenging the standard of using stainless-steel or single-use bioreactor systems to produce biologics by instead leveraging its insect-based biotechnology platform. Rather than produce a recombinant protein in single bacteria, yeast or mammalian cells, the firm uses InsectaPro, its platform comprising of…

Astrea buys filtration firm ELS and hints at more acquisitions

Astrea Bioseparations has acquired Essential Life Solutions (ELS) adding a chromatography column portfolio and operations in the US. The deal, financial details of which have not been divulged, closed last week bringing Astrea the SNAP brand of chromatography column products for research and small-scale purification of biological products. “SNAP columns are high precision, glass columns used with HPLC/FPLC systems for development of purification processes and lab scale chromatography,” Astrea told this publication. The range will complement Astrea’s bioprocess offering, which…

PendoTECH looks to compact photometer for post-filtration turbidity measurements

PendoTECH has upgraded its single use turbidity measurement system to improve performance, dynamic range, and overall usability Turbidity is the relative clarity of a liquid as the result of suspended solids in the liquid. Turbidity measurements typically use a beam of light to detect the presence of particles by measuring the difference between the amount of light that is emitted from a light source and the amount that is received by a detector. Measurements are affected by the size, shape,…

New technologies can solve downstream bottlenecks says expert

Biopharma needs to embrace new downstream processing technologies to overcome its manufacturing issues, according to an expert. Industry is reluctant to adopt new downstream technologies because firms prefers systems with which staff are familiar, said Alois Jungbauer from the Austrian Centre of Industrial Biotechnology at the University of Natural Resources and Life Sciences. He began by asking delegates at the BPI Europe virtual conference in July: “Why is chromatography so popular? “It’s the high selectivity. It’s the high resolution. We…

Cold play: Cryoport buying temperature-controlled logistics firm CRYOPDP

The €49 million ($58 million) deal ups Cryoport’s logistics services, filling out its global offering to support cell and gene therapies as well as other life science functions. French logistics firm CRYOPDP has over 220 employees in 22 global facilities across 12 countries, supporting the life sciences industry through temperature-controlled logistics products and services. The all-cash €49 million transaction, expected to complete in the next two months, will see the firm incorporated into Cryoport, expanding the firm’s global footprint and…

Automation can help biopharma enjoy the benefits of continuous processing says CPI

Automation can eliminate downstream bottlenecks and help pharma cut costs says the team behind a continuous downstream processing system at the UK Centre for Process Innovation. Manufacturing biopharmaceutical is a complex, time consuming and costly process. Most products are produced in batches – production runs through a series of steps and then ends. Batch production is reliable and able to make consistent product. However, it can be slow and expensive according to Stuart Jamieson, head of research at the CPI,…

The CHO must go on? Bioinformatics and gene editing reshaping cell line dev

Computational analysis and gene editing will yield CHO cells able to make protein drugs, faster and more cheaply says expert. The ability to turn cells into protein production “factories” is the foundation of modern biopharma according to Bjørn Voldborg, director of CHO cell line development at the Technical University of Denmark. “If you want to engineer a factory [cell line] you need to understand what machines you have in the factory. It’s the genome sequences of the CHO cells –…

Robust first half results as Repligen feels COVID-19 tailwinds

A robust quarter included a ramp-up in COVID-19-related orders, something Repligen says will set the scene for increased revenues in the second half of 2020. “Our results for the second quarter and through the first half of 2020 have been stellar,” Repligen CEO Tony Hunt told stakeholders last week. “We delivered overall revenue growth of 25%, including organic growth of 19% in the second quarter.” This equates to $164 million for the first half, compared to $131 million over the…

Danaher: Integrating Cytiva in the time of coronavirus

Cytiva, the former GE Healthcare Life Sciences business, is “off to a blistering start” at Danaher, according to an analyst despite face-to-face restrictions imposed by COVID-19. For the second quarter 2020, Danaher Corporation reported revenues of $5.3 billon, up 19% year-on-year. This was attributed to high sales across its life sciences services divisions, including a boost from Cytiva – previously known as the Biopharma Business of GE Life Sciences – which Danaher acquired for $21 billion and became part of…

COVID-19 revenue key to Thermo Fisher’s revenue growth in Q2

Thermo Fisher’s revenue increased 10% in the second quarter thanks to $1.3 billion generated by COVID-19 related work. Thermo posted revenue of $6.92 billion, up from $6.32 billion in the comparable quarter last year. Life sciences solutions contributed $2.60 billion – up from $1.71 billion – specialty diagnostics brought in $990 million – up from $940 million – and lab products and services generated $2.79 billion, up from $2.63 billion. In contrast, analytical instrument revenue was $1.05 billion, down from $1.32 billion…